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Abstract
Background The management of acne in adult females is
problematic, with many having a history of treatment
failure and some having a predisposition to androgen
excess. Alternatives to oral antibiotics and combined oral
contraceptives (COCs) are required.
Objective Our aimwas to conduct a hybrid systematic review
of the evidence for benefits and potential harms of oral
spironolactone in the management of acne in adult females.
Methods The review was conducted according to a previ-
ously published protocol. Three reviewers independently
selected relevant studies from the search results, extracted
data, assessed the risk of bias, and rated the quality of the
evidence using the Grading of Recommendations Assess-
ment, Development and Evaluation (GRADE) approach.
Results Ten randomized controlled trials (RCTs) and 21
case series were retrieved. All trials were assessed as being
at a ‘high risk’ of bias, and the quality of evidence was
rated as low or very low for all outcomes. Apart from one
crossover trial that demonstrated statistical superiority of a
200 mg daily dose versus inflamed lesions compared with
placebo, data from the remaining trials were unhelpful in
establishing the degree of efficacy of lower doses versus
active comparators or placebo. Menstrual side effects were
significantly more common with the 200 mg dose; fre-
quency could be significantly reduced by concomitant use
of a COC. Pooling of results for serum potassium sup-
ported the recent recommendation that routine monitoring
is not required in this patient population.
Conclusion This systematic review of RCTs and case
series identified evidence of limited quality to underpin the
expert endorsement of spironolactone at the doses typically
used (B100 mg/day) in everyday clinical practice.
Key Points
Oral spironolactone is used off-label to treat
persistent and late-onset acne in adult females.
There is low-quality evidence for benefits and side
effects from randomized controlled trials and case
series; superiority over placebo has not been
established for doses\200 mg/day.
Prescribing recommendations must continue to rely
on consensus and expert opinion until high-quality
evidence becomes available.
1 Introduction
Acne is the eighth most prevalent disease globally [1].
While this chronic inflammatory skin condition affects
mostly adolescents, adult females represent a significant
and increasing proportion of cases in which quality of life
is severely affected [2–5].
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A number of variants of acne in adult women are rec-
ognized, based on age of onset, distribution and type of
lesions, recalcitrance to conventional drug-based remedies,
predisposing factors (e.g. smoking, ethnicity), and endo-
crine disposition, most commonly polycystic ovarian syn-
drome (PCOS) [2, 3, 6–9]. However, many patients have
no signs of peripheral hyperandrogenism other than acne.
Serum profiles of androgens and gonadotrophins are often
normal [10, 11].
In both teenagers and adults, acne is, de facto, a disease of
sebogenesis [12]. Beginning during adrenarche, rising levels
of androgens and insulin-like growth factor (IGF)-1 mediate
the onset of sebum production in both sexes [13]. Anaerobic
bacteria, particularly Propionibacterium acnes proliferate
within acne-prone pilosebaceous follicles, which are
blocked as a result of abnormal keratinocyte proliferation in
response to signals from sebum components. This triggers
leukocyte infiltration via both innate and adaptive immune
mechanisms. Characteristically, a cell-mediated inflamma-
tory response ensues, in which macrophages and T helper
(Th)-1 and Th-17 cells predominate [13, 14].
Spironolactone, a synthetic 17-lactone steroid, acts as a
non-selective mineralocorticoid receptor antagonist with
moderate affinity for both progesterone and androgen
receptors [15]. Spironolactone is predominantly utilized in
clinical practice as a potassium-sparing diuretic, however it
has been used off-label for acne since the 1980s. A
reduction in sebum may be achieved by blocking dihy-
drotestosterone binding to the androgen receptor within
sebocytes and inhibiting androgen-induced sebocyte pro-
liferation [16, 17]. The systemic effects of spironolactone
on adrenal synthesis of androgen precursors may also
contribute to clinical efficacy, although at therapeutic doses
this may be unlikely [18]. The diuretic effect of spirono-
lactone may benefit women who experience a premenstrual
acne flare associated with fluid retention [19].
Successful long-term management of acne in adult
women presents a considerable therapeutic challenge. As
an anti-androgen and potential inhibitor of sebogenesis,
spironolactone represents a possible alternative to oral
isotretinoin and combined oral contraceptives (COCs), the
only licensed anti-acne medications that significantly
reduce sebum secretion, but which may be associated with
serious adverse effects in some patients [20, 21]. Antibi-
otics are often over-prescribed in acne, drive antimicrobial
resistance in targeted and non-targeted bacteria, and have
no effect on sebum synthesis [22].
A Cochrane review focusing primarily on hirsutism
included only one randomized controlled trial (RCT) of
oral spironolactone for acne in its analyses and concluded
there was insufficient evidence for effectiveness in treating
acne [23]. In contrast, a narrative review, based largely on
clinical experience, highlighted the potential therapeutic
usefulness of oral spironolactone in the management of
acne in adult females, and detailed recommendations about
appropriate use and monitoring during therapy [24].
Take-home messages from these different reviews are
contradictory. In view of this clinical uncertainty, we
conducted a hybrid systematic review of all studies that had
assessed the clinical efficacy of oral spironolactone for
acne in women. The primary aim was to determine whether
oral spironolactone monotherapy produces a degree of
improvement in acne that is clinically important and
comparable to conventional drug-based remedies. Sec-
ondary aims were to identify evidence that could better
inform clinicians on the selection of patients likely to
benefit, and/or reveal the most appropriate dosing regimen.
2 Methods
The protocol for this review was published in PROSPERO
(http://www.crd.york.ac.uk/PROSPERO/) with the acces-
sion number 42016038496.
2.1 Search Strategies
Electronic searches were conducted between 10 and 15
May 2016 and included the Cochrane Central Register of
Controlled Trials, MEDLINE, EMBASE, Science Citation
Index and LILACS. The search strategy for MEDLINE and
EMBASE is shown in Appendix 1 (electronic supple-
mentary material). The following trials registers were
searched using the search terms spironolactone AND acne
or ‘polycystic ovarian syndrome’.
• metaRegister of Controlled Trials (www.controlled-
trials.com);
• US National Institutes of Health Ongoing Trials
Register (http://www.clinicaltrials.gov);
• Australian New Zealand Clinical Trials Registry (http://
www.anzctr.org.au);
• World Health Organization International Clinical Trials
Registry Platform (www.who.int/trialsearch);
• EU Clinical Trials Register (https://www.
clinicaltrialsregister.eu/).
The reference lists of all identified RCTs and key review
articles were checked for citations to potentially relevant
studies. No language or date restrictions were applied.
Outputs of searches were imported into Rayyan to
facilitate sorting [25], and full-text copies of all potentially
eligible studies were obtained. Two authors (AE and ZF)
independently assessed the full-text papers and resolved
any disagreements on the eligibility of included studies
through discussion and consensus, or through a third party
(EvZ).
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2.2 Inclusion Criteria
We included RCTs in females of any ethnicity over
18 years of age with acne vulgaris of the face and/or trunk,
or PCOS if acne status or severity was measured as an
outcome. Case series were included if they provided sup-
plementary evidence on the benefits or side effects.
2.3 Outcome Measures
The following primary outcomes were prespecified: (1)
physician-assessed change in total lesion count; and (2)
physician-assessed change in global acne severity using a
recognized or validated scale. Prespecified secondary out-
comes were (1) participant-reported improvement in global
acne severity (e.g. Likert scale); (2) change in health-re-
lated quality of life (HRQOL) assessed using any validated
instrument (generic, dermatology-specific, or acne-speci-
fic); (3) number and proportion of participants reporting
each type of adverse event; (4) duration of remission post-
treatment; and (5) time to improvement (as assessed by
either primary outcome or patient-reported outcome at time
points within the first 8 weeks).
2.4 Data Extraction
Data extraction using piloted forms, risk of bias assessments
and analyses were carried out independently by three authors
(AE, ZF and EvZ) and any disagreements were resolved by
consensus. Risk of bias assessments for the RCTs were made
using the Cochrane domain-based risk of bias tool and were
used to support conclusions regarding the overall quality of
evidence in the review [26]. Data were analyzed using
RevMan version 5.3 [27]. Dichotomous outcomes were
expressed as risk ratios (RRs) and were reported with their
associated 95% confidence interval (CI), while continuous
outcomes were reported as mean differences (MDs) with
95% CI. Attempts, although only partially successful, were
made to obtain missing trial details by contacting the lead
investigators of the studies. The protocol specified that data
would be reanalyzed according to the intention-to-treat
(ITT) principle; however, for the majority of trials this was
not possible due to inadequate or incomplete reporting.
Therefore, in general, the per-protocol (PP) population was
used. Analyses of side effect rates were conducted using the
ITT populationwith andwithout acne. For numbers included
in each type of analysis, see Electronic Supplementary
Table 1. When available, and unless otherwise stated,
assessments at month 3 were used as the basis of comparison
between studies. The Grading of Recommendations
Assessment, Development and Evaluation (GRADE) soft-
ware (GRADEpro GDT) was used to rate the quality of
evidence from RCTs for the individual outcomes and to
produce summary of findings tables [28]. Following rec-
ommendations in the GRADE handbook, case series are
considered to provide low quality evidence and are often
further downgraded to very-low-quality evidence [29]. Data
from case series were not reanalyzed but were pooled if the
studies were clinically similar.
3 Results
3.1 Study Characteristics
Full details of the study selection process are reported in
Fig. 1.We identified10RCTs [30–39], 18case series inwhich
acne status or severity was an outcome [40–52, 54, 55, 57,
59, 60], and three [53, 56, 58] articles reporting on the side
effects of spironolactone in female patients with acne, but
which contained no data on clinical outcomes. Eleven studies
[61–71]were out of scope and fivewere unobtainable [72–76]
(see Electronic Supplementary Table 2).
3.2 Randomized Controlled Trials (RCTs)
All 10 RCTs were single-center studies that had been
conducted in Canada (1), UK (2), India (3), Bangladesh
(1), Thailand (1), Israel (1) and China (1). Baseline acne
severity ranged from mild to severe and was not reported in
four trials [30, 32, 34, 39]. The sites affected by acne were
reported for seven trials and always included the face
[31–33, 35, 36, 38, 39]. Of the four trials that included
males, two reported results for females separately [33, 39]
and two did not [31, 36]. Six trials did not mention any
sources of funding [31, 33, 36–39], one was funded by a
manufacturer of spironolactone [30], two were funded by
non-industrial sponsors [34, 35] and one received no sup-
port from a pharmaceutical company [32]. A spironolac-
tone manufacturer supplied the active and placebo
treatment in two trials [31, 37]. Declarations stating no
conflicts of interest were provided for two trials [32, 35].
For further details, see Table 1.
3.2.1 Risk of Bias in Included RCTs
All of the trials were considered to be at ‘high risk of bias’
(plausible bias that seriously weakens confidence in the
results) because one or more domains, most commonly
lack of blinding, received a judgment of high risk (see
Fig. 2).
3.2.2 Use of Outcome Measures Within the RCTs
Heterogeneity of outcome measures and methods of
reporting meant that pooling of data from different trials
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versus the same comparator was not feasible. Only two
studies [31, 37] reported the same outcome in the same
way for a similar patient population. Of our primary out-
comes, four trials included a lesion count [36–39] and five
included an investigator-assessed change in global acne
severity, all but one of which used recognized but different
severity scales [32–35]. Of our secondary outcomes, three
trials included participant-assessed global improvement
[31, 32, 37], none measured changes in HRQOL and only
two included a post-treatment follow-up [30, 34]. One trial
included time points prior to month 3, theoretically
enabling calculation of time to improvement [30].
All but one trial reported side effects in full; one
reported side effects associated with discontinuation only
[34]. Only two trials reported the number of women
experiencing any side effect [32, 38]. Seven trials moni-
tored changes in serum potassium (risk of hyperkalemia),
but none reported the number of women with raised levels
as a result of treatment [31–33, 35, 36, 38, 39].
3.3 Effect of the Interventions
The ten RCTs included 16 comparisons of spironolactone
versus placebo or active treatment. The quality of the
evidence was assessed for all comparisons and was
downgraded by several levels, principally due to limita-
tions in study design and implementation, and imprecision
due to low sample sizes, and was consequently rated low or
very low for our predefined outcomes. Inadequate data
reporting did not permit calculation of RRs or MDs for any
of the outcomes in four trials [30, 31, 34, 36].
3.3.1 Spironolactone versus Placebo
Three trials evaluated this comparison [31, 36, 37]. One
provided useful data for a 200 mg daily dose in a crossover
trial that examined 29 women [37]. For the inflamed lesion
count, the MD in favor of spironolactone was 26.1 lesions
fewer, despite baseline imbalance in favor of the placebo
(p\ 0.00001; PP population of 21, both phases combined).
Data for the first phase, which would be free of any
potential carryover effects, were not reported. Combined
data from both phases showed that 18/21 women taking
spironolactone, compared with 5/21 taking placebo,
reported improvement (RR 3.6, 95% CI 1.64–7.89;
p = 0.001), and 15/20 versus 4/20 had at least a 50%
reduction in inflamed lesion count (RR 3.75, 95% CI
1.51–9.34; p = 0.005). In a mixed gender RCT [36], 24/30
LILACS Latin American and Caribbean Health Sciences Literature, CENTRAL Cochrane Central Register of Controlled Trials, RCT randomized 
controlled trial
Number of records identified from database searches
Medline n = 132
Embase n = 487
LILACS n = 142 
Science Citation Index n = 187
CENTRAL n = 25
Number of records from 
other sources n = 1 
Number of records after duplicates removed n = 541
Number of records screened n = 541 Number of records excluded n = 494
Number of full text articles assessed 
for eligibility n = 47
Number of full text articles excluded with reasons n = 11
• RCT but wrong age range (<18 y) 1
• Case series, acne not a reported outcome 2
• Case series, acne data not extractable 1
• Review but not indexed as one 2
• Topical delivery 3 
• Acne as a side effect 2 
Articles not yet obtained n = 5 including 2 probable duplicate publications 
Number of records from 
trial databases n = 0
Number of full text articles retained and 
included in evidence synthesis
• RCT n = 10
• Case series n = 18 
• Reports of adverse events but no 
clinical outcomes n = 3
Fig. 1 Study flow diagram
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participants receiving spironolactone (50 mg/day, includ-
ing 27 women) improved, compared with 2/25 receiving
placebo (PP population); separate data were unavailable for
females. A similar problem arose in the third trial, which
also included males [31]. Data could not be extracted for
three women receiving the 50 mg dose, but 6/9 women
receiving doses of 100–200 mg/day improved, irrespective
of which outcome measures were used (PP population). In
neither mixed gender trial was the extent of improvement
quantified. For details and quality of evidence, see Table 2.
3.3.2 Spironolactone versus Cimetidine
Three trials compared spironolactone with cimetidine using
different daily doses of one or both drugs and different
outcome measures [33, 38, 39]. One also used a shorter
treatment duration (2 months) and an unspecified topical
therapy in both arms [39]. Despite these inconsistencies,
none detected a difference in efficacy between the two
drugs. The earliest trial [33] found no difference in acne
severity score between spironolactone (100 mg/day) and
cimetidine (1.6 g/day) [MD -4.20, 95% CI -17.48 to
9.08; p = 0.54] using the Michae¨lsson scale [78]. Simi-
larly, the second study [38] found no difference between
the same dose of spironolactone and cimetidine 1.4 g/day,
using reduction in inflamed and non-inflamed lesions as the
outcome measure. MDs were -3.3 inflamed lesions (95%
CI -8.14 to 1.54; p = 0.18) and -10.70 non-inflamed
lesions (95% CI -24.08 to 2.68; p = 0.12). Lesion counts
were also converted to a categorical improvement in 11/15
women receiving spironolactone and 6/14 women receiv-
ing cimetidine, showing at least a 50% reduction in lesions
(RR 1.71, 95% CI 0.87–3.37; p = 0.12). In the final trial
[39], a lower dose of spironolactone (60 mg/day) was not
significantly different to cimetidine for the number of
participants with at least 50% reduction improvement
(physician-assessed) at an initial dose of 1.2 g/day (RR
0.96, 95% CI 0.89–1.03; p = 0.25). For details and quality
of evidence, see Electronic Supplementary Tables 3 and 4.
3.3.3 Spironolactone Plus a Combined Oral Contraceptive
(COC) versus the Same or a Different COC Alone
or Combined with an Anti-Androgen
Among the remaining comparisons, four compared
spironolactone in combination with a COC versus a COC
alone [35] or combined with an anti-androgen: flutamide
[30], finasteride [34] or additional cyproterone acetate [32].
One trial compared 25 mg/day spironolactone plus deso-
gestrel/ethinyl estradiol (EE) versus cyproterone acetate/
EE [35]. Assessed using the global acne grading system
[80], both treatments were similarly effective in reducing
the acne severity score from baseline, with an MD of -2.0
(95% CI -4.59 to 0.59; p = 0.13). For details and quality
of evidence, see Electronic Supplementary Table 5.
A second trial compared spironolactone (100 mg/day)
plus norgestimate/EE with (1) norgestimate/EE alone and
(2) cyproterone acetate/EE plus 10 mg/day additional
cyproterone acetate [32]. Randomization was 3:3:1, with
fewer women in the norgestimate/EE arm. After 12 months
of treatment, no significant difference was reported in the
proportion of women with at least 50% improvement, using
the Burke and Cunliffe acne grading system [81], between
the three arms. Participants’ self-assessed improvement
confirmed these data. For details and quality of evidence,
see Electronic Supplementary Tables 6 and 7.
The remaining two trials employed multiple assessment
time points, which, in one case, included the first and
second month of treatment [30], and included post-treat-
ment follow-up for 6 months (Table 4). Neither conducted
any intergroup tests of significance and both presented data
graphically, with no measures of dispersion of mean val-
ues, therefore MDs could not be calculated. Hence, the
studies provided limited usable data. Using the Indian
grading system [79], one study [34] found no difference in
the rate of improvement or magnitude of the reduction in
severity score for spironolactone plus cyproterone acetate/
EE compared with finasteride plus the same COC
(p[ 0.05 for all time points, investigators’ calculation).
The reduced acne severity score (10% of baseline value at
month 12) was maintained almost unchanged during the
6-month post-treatment follow-up period. The other trial
[30] compared spironolactone plus levonorgestrel/EE ver-
sus flutamide plus the same COC using the Cremoncini
score [77], which included seborrhea and alopecia as well
as acne. The score fell more rapidly in the flutamide plus
COC arm and the reduction in score, which was maximal
by month 3 in both groups, was also greater for the com-
parator (50% vs. 85% reduction; statistical significance not
reported by the investigators. At month 9 (end of the
treatment phase), 5/10 or 7/10 in the spironolactone arm
(investigators’ text unclear) versus 11/12 in the flutamide
arm had a lower severity score [30]. Relapse occurred over
6 months in both arms. For further details and quality of
evidence, see Electronic Supplementary Tables 8 and 9.
3.3.4 Spironolactone versus Ketoconazole
and Tetracycline
Spironolactone (60 mg/day) was compared with (1)
200 mg/day ketoconazole and (2) oral tetracycline at an
initial de-escalating dose of 1 g/day [39]. All three treat-
ments were similarly effective using the proportion of
women with at least 50% improvement in lesion count as
the outcome measure (Table 4). However, as the numbers
of participants in each treatment arm were not equal, the
174 A. M. Layton et al.
Fig. 2 Risk of bias summary:
authors’ judgments about each
risk of bias item for every
randomized controlled trial
included. ? indicates low risk,
- indicates high risk, ?
indicates unclear risk of bias
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study may not have been sufficiently powered to detect a
difference between spironolactone (n = 63) and tetracy-
cline (n = 14). For details and quality of evidence, see
Electronic Supplementary Tables 10 and 11.
3.4 Supplementary Efficacy Data from Case Series
and Comparison with RCTs
Of the 18 case series, 13 were in English, two in Spanish,
and one each in French, Czech and Turkish. As well as
these, three additional articles included some data on side
effects in women with acne [53, 56, 58]; they did not
address clinical effectiveness. One definite case series [74]
(in Portuguese) and two possible case series (in Czech)
including acne patients treated with spironolactone [72, 75]
were unobtainable and had either no abstract or an unin-
formative abstract. Two further unobtainable articles, one
in Spanish [73] and one in Turkish [76], had abstracts
containing sufficient information to identify them as
duplicate publications of two included case series [44, 60].
Acne severity ranged from mild to severe and was not
reported in nine of the case series [41, 43, 45, 46, 50–52,
54, 55]. The location of lesions was reported in only three
case series [48, 54, 57]. Seven studies did not make a clear
statement about concomitant medications, making attribu-
tion of any clinical effect to spironolactone uncertain
[41, 43–45, 49, 51, 55]. Further details are reported in
Table 3. Insufficient data were provided to conduct any
subgroup analyses on the effect of dose or duration of
spironolactone therapy on efficacy or side effects. Within
the case series, between 216 and 259 of 728 women
(29.7–35.6%) were receiving daily doses of C150 mg,
compared with only 35/343 women (10.2%) in the RCTs.
The most commonly used outcome measure was
physician-assessed global improvement in acne severity,
which was reported in all but three case series [46, 49, 54].
Some used a 4- or 5-point Likert-like improvement scale,
whereas others simply recorded improved/not improved
without further categorization. Dichotomizing the pooled
data shows that acne improved (to any extent) in 427/550
women (77.6%, ITT population) receiving spironolactone
at any dose. Using the PP population, the proportion who
improved was 427/454 (94.1%). These improvement rates
are significantly higher than in the RCTs that also assessed
this outcome (164/213, 76.1%; PP population, not calcu-
lable for ITT population due to incomplete reporting; RR
1.22, 95% CI 1.13–1.32; p\ 0.00001).
The only other clinical outcomes reported in the case
series were change in acne grade [43, 59], change in lesion
count [54, 60] and post-treatment relapse rate [40, 60].
Using their own grading method [81], Burke and Cunliffe
[43] observed a 35% reduction in acne severity at month 3,
and an average 52% reduction at month 6, in eight women
receiving a spironolactone dose of 200 mg/day (no mea-
sures of dispersion or p values were reported). Turowski
and James [59] recorded a dramatic improvement in acne
score in 39 women, from a median of two pretreatment to
eight post-treatment (no measure of dispersion) on a scale
of 1–10 (lower is worse). Most of the women in this study,
which used spironolactone doses of 50–100 mg/day, were
receiving concomitant medications and were treated for an
average of 19.5 months. In the study by Yemisci et al. [60],
the mean lesion count in 28 women (PP population) had
decreased by month 3, from 32.86 (standard deviation [SD]
16.15) to 6.92 (SD 4.99), a reduction of 78.9% with
spironolactone monotherapy at 100 mg/day (p\ 0.001,
investigators’ calculation). Furthermore, in the study by
Saint-Jean et al. [54], the mean inflamed lesion count fell
from 9.0 to 4.6, and the non-inflamed lesion count fell from
15.0 to 8.5 (no measures of dispersion and no p-values) in
14 women treated with a spironolactone dose of
75–150 mg/day for an average of 17 months. Two studies
[46, 51] did not report any quantifiable outcomes data and
two followed-up patients after treatment ended [40, 60]. In
the study by Azizlerli et al. [40], 5 of 14 women (35.7%)
followed for 3–18 months relapsed, while in the study by
Yemisci et al. [60], acne returned in 5/28 women (17.9%)
during the 6-month follow-up period. Interestingly, Bravo
Garcia et al. [42] observed that residual acne post-treat-
ment in 23/30 women was purely comedonal, whereas only
10/53 had exclusively comedonal acne prior to treatment
(p\ 0.00001, Chi-squared).
3.5 Side Effects Reported in RCTs and Case Series
None of the studies carried a clear statement as to how
information on side effects had been elicited, e.g. sponta-
neous reporting versus an open-ended question at each
visit. Within the RCTs, there was no difference in the
proportion of participants who dropped out due to side
effects: 14/303 (4.6%) receiving spironolactone at any dose
versus 10/343 (2.9%) receiving the comparators (RR 1.58,
95% CI 0.71–3.52; p = 0.26). Dropout rates due to side
effects could not be calculated for two trials [31, 36]. In the
case series, 49/729 (6.7%) women dropped out due to the
side effects of spironolactone (ITT population). This was
not significantly different to the rate in the RCTs (RR 0.69,
95% CI 0.39–1.23; p = 0.20).
Due to inadequate reporting in 8/10 RCTs, the propor-
tion of women experiencing any side effect(s) could not be
calculated [30, 31, 33–37, 39]. In the case series, at least
241 women experienced side effects equivalent to 48.0% of
the PP and 43.9% of the ITT population. Reported rates
varied from 0 to 90.7%, with the highest rates associated
with the 200 mg/day dose [46, 55]. The most common side
effect in both the RCTs and case series was menstrual
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irregularities: 38/264 (14.4%) in the RCTs and 216/543
(39.8%) in the case series (RR 0.36, 95% CI 0.26–0.49;
p\ 0.00001). From the case series, it was apparent these
were dose-related: 137/176 women receiving 200 mg/day
experienced menstrual disturbances, compared with 66/349
on lower daily doses (RR 4.12, 95% CI 3.27–5.19;
p\ 0.00001).
Within the RCTs, it was possible to compare the inci-
dence of menstrual disturbances in women receiving
spironolactone with and without concomitant use of a
COC. The incidence appeared significantly lower when
spironolactone was combined with a COC: 32/146 without
a COC versus 6/112 with a COC (RR 0.24, 95% CI
0.11–0.56; p = 0.001). This was also observed by Hughes
and Cunliffe [46], who studied the incidence of side effects
in a series of 53 women receiving a dose of 200 mg/day.
The number of women with menstrual irregularities was
12/23 receiving a COC versus 21/24 receiving spirono-
lactone monotherapy (RR 0.60, 95% CI 0.39–0.91;
p = 0.02). In a minority of women with abnormal menses,
spironolactone therapy was reported to normalize the
menstrual cycle [41, 52, 57].
Other commonly reported side effects in the RCTs and
case series are shown in Table 4. No side effect, apart from
menstrual disturbances, had an incidence above 5% in the
RCTs or case series. Uncommon side effects (0.1–1.0%)
were postural hypotension, depression, diarrhea, muscle
pain, increased appetite, drowsiness, rashes/drug eruptions,
chloasma-like skin pigmentation, polydipsia, weakness,
edema of the legs, change in libido, and palpitations. Some
investigators mentioned that certain side effects were
considered beneficial: breast enlargement, reduced
symptoms of premenstrual syndrome, and less greasy skin
and hair [31, 46, 57]. Due to the use of concomitant
medications, especially COCs, in many of the studies, side
effects could not be unambiguously attributed to spirono-
lactone. Among the 10 case series of spironolactone
monotherapy in 370 women in which concomitant thera-
pies were not mentioned [41, 43–45, 49, 51, 55] or were
not permitted [42, 52, 60], the only common side effects
reported were nausea (11), abdominal pain (C10), polyuria
(4) and breast tenderness (4).
3.6 Risk of Hyperkalemia
Serum electrolytes were measured in 7/10 RCTs
[31–33, 35, 36, 38, 39] involving 157 women (PP popu-
lation) and 10/18 case series [41, 45, 47, 49–52, 55, 57, 60]
involving 312 women (PP population) as a means of
detecting possible adverse effects of spironolactone on
fluid balance and kidney function. Serum electrolyte data
reporting was inadequate in almost all cases and no results
were presented for two RCTs that monitored this [36, 38].
No women in the remaining five RCTs were reported to
have elevated levels. Fourteen women (4.5%) in two case
series [51, 57], one that used doses C200 mg/day (4/18)
and the other 50–100 mg/day (10/73), were reported to
have slightly raised levels post-treatment. In an earlier
study (not one of the 18 case series), serum potassium was
measured in otherwise healthy women with acne treated
with 50–150 mg/day of spironolactone [56]. Mild hyper-
kalemia was detected in 6/60 (10%) women. It is impos-
sible to determine whether the women in the later study
were a separate group to those in the earlier study, and thus
Table 4 Summary of common and very common adverse side effects of spironolactone (C1% of the ITT population for RCTs and/or case
series)
Side effect RCTs (eligible ITT population = 326 unless
stated)
Case series (eligible ITT population = 663 unless
stated)
Number % Number %
Menstrual irregularities 38 13.4 (of 283) 216 33.4 (of 646)
Breast tenderness 8 2.5 30 4.5
Breast enlargement 7 2.1 13 2.0
Dizziness/vertigo/lightheadedness 11 3.4 At least 19a C2.9
Headache 5 1.5 At least 10a C1.5
Nausea with/without vomiting 6 1.8 24 3.6
Weight gainb 5 1.5 1 0.2
Abdominal pain 0 0 At least 11a C1.7
Polyuria 2 0.6 8 1.2
Fatigue/lethargy 1 0.3 At least 12a C1.8
ITT intention to treat, RCTs randomized controlled trials
a Precise figures not available due to inadequate reporting
b Not monitored in most studies
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whether these were independent samples. Most recently,
Plovanich et al. [53] conducted a retrospective analysis of
serum potassium levels in 974 women aged 18–45 years
taking 50–200 mg/day of spironolactone for acne, seen in
two US hospitals between December 2000 and March
2014. Among 1802 measurements, 13 were slightly ele-
vated, yielding a mild hyperkalemia rate of 0.72%, similar
to the expected baseline rate of 0.76% derived from all
available serum potassium measurements for females of
the same age (32/4209). Repeat testing in 6/13 women
yielded values within the normal range, suggesting initial
measurements could have been erroneous.
4 Discussion
Two authors of this review (JDR, AML) confirm that,
based on their extensive experience of successful use of the
drug to treat large numbers of women with persistent or
late-onset acne, spironolactone is pivotal to their clinical
practice. Such experience suggests that the important role
of spironolactone in this hard-to-manage patient population
has been largely underrecognized and provided the ratio-
nale for this systematic review. What the review has
highlighted is a paucity of high-quality evidence for the
effectiveness of oral spironolactone in the management of
acne in adult females. The results should not be misinter-
preted to mean that the drug is ineffective at safe dosages,
but rather that there is a lack of robust evidence in support
of expert opinion, which currently drives treatment rec-
ommendations either for or against more widespread use.
Every one of the 10 RCTs was at high risk of bias, with
the most common reason being lack of blinding. Even in
the more recent trials, sample sizes were not justified by
reporting of power calculations or the assumptions on
which they had been based. This lack of difference in
efficacy between treatments might have been due, at least
in part, to insufficient power. Moreover, as no single out-
come measure had been used consistently across the trials,
pooling of data from similar comparisons was not possible.
The trials fell into two categories: (1) comparisons of
spironolactone monotherapy versus placebo; and (2) com-
parisons of mono or combination therapy versus active
treatment. GRADE assessments of the quality of the evi-
dence showed that all of the comparisons versus placebo
were rated ‘very low quality’ and all of the comparisons
versus active therapy were of low or very low quality. With
one exception [39], the choices of active comparator did
not include standard oral therapies such as antibiotics or
isotretinoin, nor was there any direct head-to-head com-
parison of spironolactone monotherapy with a COC of
proven anti-acne efficacy, such as cyproterone acetate plus
ethinyl estradiol.
Despite the somewhat limited evidence available, some
tentative conclusions can still be drawn. First, at a daily
dose of 200 mg, spironolactone was found to be signifi-
cantly superior to placebo versus inflamed lesions in a
crossover trial in which 21 of 29 women completed
3 months of treatment. Baseline imbalance and a possible
carryover effect of spironolactone into the second phase
would have reduced the magnitude of the difference in
efficacy between spironolactone and placebo, which was
already large. This statistically significant result was not
reported by the authors of a frequently cited Cochrane
review, which evaluated the effects of spironolactone for
hirsutism and acne [23]. Equally, the Cochrane review may
have also inadvertently misled authors of subsequent
reports by stating that ‘‘there was no evidence for effec-
tiveness [of spironolactone] for the treatment of acne vul-
garis’’. In contrast to the crossover trial, no conclusions can
be drawn from the two parallel group comparisons versus
placebo regarding the absolute efficacy of lower doses of
spironolactone. Spironolactone appeared to be more
effective than placebo, but by how much was not quantified
and indeed the difference may not have been clinically
significant. The very-low-quality evidence provided by the
case series consistently shows that lower doses do have a
measure of anti-acne activity, but they contributed no
information on relative efficacy.
The trials that assessed comparative efficacy versus the
anti-androgens flutamide, finasteride, cimetidine, keto-
conazole and various COCs consistently found no differ-
ence between the spironolactone arm and the anti-androgen
arm. With the exception of the COCs for which anti-acne
efficacy has been established beyond doubt [83], indepen-
dent verification of the efficacy of the comparators is scarce
and/or contradictory [84–92]. What these anti-androgens
have in common with spironolactone and COCs is the
expectation that they will reduce sebum secretion at the
doses used via their effects on androgen synthesis, action or
sequestration (see Table 5). Demonstrating no difference in
efficacy versus these agents is unhelpful in terms of
quantifying the effect size for spironolactone, especially as
some of the trials most likely had too few participants to
detect a significant difference, if in fact such a difference
existed.
Four of the RCTs evaluated spironolactone in combi-
nation with a COC. Hirsutism or PCOS was the primary
diagnosis and acne was the secondary diagnosis. Since
COCs are potent anti-androgens, and are effective as
monotherapy for acne, superiority of the combination
needs to be demonstrated over the COC alone. Despite this,
only one trial included a COC monotherapy arm and found
no benefit of adding spironolactone to norgestimate/EE
[32], although, at trend, the combination was more effec-
tive. In this three-arm trial, treatment allocation was
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unbalanced, with three times as many women in the
combination arm as those receiving COC monotherapy.
Any added benefit of spironolactone might have been
revealed had treatment arms been of equal size.
One potentially more useful trial put spironolactone
head-to-head against oral tetracycline and found no dif-
ference in efficacy over 8 weeks of treatment [39]; how-
ever, caution is necessary in interpreting the results as this
trial was also unbalanced, with 63 women receiving
spironolactone but only 14 receiving tetracycline. Inter-
estingly, the duration of therapy was consistently short
(2–3 months) for those RCTs in which acne was the pri-
mary diagnosis, and much longer (9–12 months) for the
trials in which hirsutism was the primary diagnosis. After
only 3 months of treatment, the response of acne to
spironolactone may not be optimal. The case series show
that clinicians often use longer courses to manage acne in
the real world. Using the PP population, improvement rates
were significantly higher in the case series compared with
those RCTs that had also used an outcome measure that
could be dichotomized. This difference in efficacy rates
may be an indication that longer treatment is likely to be
more successful.
Only two RCTs conducted time courses with post-
treatment follow-up [30, 34]. One found [30] that
improvement was maximal at month 3 (approximately
50% reduction vs. baseline), whereas the other showed that
improvement continued until month 12, when the reduc-
tion was 89% [34]. Both used 100 mg/day of spironolac-
tone in combination with a COC—the former in
combination with triphasic levonorgestrel/EE and the latter
in combination with cyproterone acetate/EE. In the follow-
up phase, acne returned to baseline levels over 6 months in
those treated with spironolactone plus levonorgestrel/EE,
but there was no relapse in those treated with cyproterone
acetate/EE. The data for the spironolactone plus levo-
norgestrel/EE combination may be somewhat misleading
as a non-validated scoring method which combined acne
with seborrhea and alopecia was used [77]. Neither study
included a COC-only or spironolactone-only treatment
arm, making it impossible to determine the contribution of
spironolactone to the efficacy of the combination.
Two studies made apparently contradictory observations
in respect of the efficacy of spironolactone against come-
donal (non-inflamed) lesions. One case series found that
residual acne was more likely to be comedonal [42],
whereas an RCT showed what appeared to be a large
reduction in comedonal acne compared with baseline and
the comparator [38]; however, the lack of reporting of
baseline data for the number of lesions in the RCT did not
permit fair comparisons to be made. As only these two
studies evaluated comedones, it is not possible to know
whether spironolactone monotherapy is effective versus
non-inflamed lesions. Expert reviews [24, 56], commen-
taries [111], and acne treatment guidelines that include
spironolactone, such as the recent US guidelines [112], are
silent on this important point. ‘Hormonal acne’ is widely
perceived as predominantly inflammatory with a paucity of
comedones; however, such cases represent a minority of
women with acne and, in most instances, comedones will
be present [113].
Dropout rates due to side effects in spironolactone-
treated participants were low in the RCTs and case series,
suggesting that most women who begin the drug will
continue to take it. However, side effect rates were sig-
nificantly higher for the 200 mg/day dose than for lower
doses. This was especially true for menstrual irregularities,
the most common side effect reported in the RCTs and case
series. Pooling of data has shown that the rate of menstrual
irregularities can be significantly reduced by concomitant
use of a COC, a practice that is widely recommended by
experts [24, 56, 111]. However, experts also recommend
dose escalation [24, 56, 111, 114, 115], which, paradoxi-
cally, was rarely used in the included trials or case series as
a potential, but as yet untested, means of improving tol-
erance and adherence.
A recent multicenter study in 974 women [53] con-
cluded that routine monitoring of serum potassium in
healthy women taking spironolactone for acne is not nec-
essary. The findings from this systematic review support
that conclusion. Occasional testing may be justified on a
case-by-case basis when risk factors are present. Although
14 women with raised potassium levels were identified
among 469 women in the RCTs and case series, hyper-
kalemia was invariably mild and clinically insignificant.
Some of the side effects of spironolactone, notably nausea,
fatigue, and especially muscle weakness, can be indicative
of hyperkalemia and, if persistent, could be used to indicate
patients in whom testing may be justified. Crucially, the
non-requirement for routine testing would reduce the
overall direct costs of spironolactone treatment.
While endorsing key aspects of expert opinion with hard
data and providing some new insights, this systematic
review has highlighted existing important gaps in the evi-
dence about how best to utilize oral spironolactone in
managing acne in women, including clarifying the opti-
mum dose and dosing regimen to maximize benefits and
minimize the risk of side effects, the lowest effective dose,
the possible requirement for concomitant therapies and
what these should be, which types of acne are likely to be
responsive, and how effective spironolactone is compared
with standard therapies. It is interesting to note that several
current acne guidelines and treatment recommendations
include spironolactone on the basis of consensus and/or
expert opinion [112, 116, 117]. Others either do not men-
tion spironolactone [118–121], or specifically say it is
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Table 6 Summary of findings from this review, and recommendations for future research to fill the evidence gap: EPICOTa
Element Issues to consider Status of research for this review and recommendations
Disease
burden
Acne is the eighth most common disease globally, with peak
prevalence in late adolescence. Acne in adult women is often
recalcitrant to conventional medications, associated with a high
degree of emotional distress and sometimes accompanied by
hyperandrogenemia and/or other signs of peripheral
hyperandrogenism, such as hirsutism and alopecia
Evidence
(E)
What is the current evidence? This systematic review identified 10 RCTs and 21 case series
that provided some evidence of the benefit and potential harms
of oral spironolactone for acne in adult females. The most
frequently reported outcome measure was physician-reported
improvement in acne severity. Lesion counts were reported for
two RCTs and none of the case series. Patient-assessed
outcomes were reported for three RCTs and none of the case
series
Results from one RCT of crossover design at high risk of bias
showed that spironolactone at a daily dose of 200 mg was
significantly more effective than placebo against inflamed
lesions (low-quality evidence, GRADE). Evidence for lower
doses with respect to comparative efficacy versus placebo or
active comparators was equivocal and of low or very low
quality. There was some very-low-quality evidence that
menstrual irregularities, the most common side effect observed
in RCTs and case series, are dose-related and can be minimized
by concomitant use of a combined oral contraceptive. Although
serum potassium levels were measured in 7 RCTs and 12 case
series, inadequate reporting meant that it was not possible to
draw robust conclusions regarding the need for routine
monitoring of hyperkalemia at any dose up to 200 mg/day in
this patient population





Diagnosis, disease stage, comorbidity, risk factors, gender,
age, ethnic group, specific inclusion or exclusion criteria,
clinical setting
Inclusion criteria:
Premenopausal females aged 18 years and over with persistent
or late-onset acne vulgaris
Acne severity defined at baseline, e.g. at least moderate severity
(IGA score of 3 on a 0–5 scale), with a minimum of 15
inflamed and 15 non-inflamed lesions on the face
Women with PCOS can be included. In addition, women with
additional signs of peripheral hyperandrogenism can also be
included as long as the endocrinopathies listed below have
been excluded
Exclusion criteria:
Pregnant or intending to become pregnant
Androgen-secreting adrenal or ovarian tumor
Cushing’s syndrome, late-onset congenital adrenal hyperplasia
Unwilling to stop oral and topical anti-acne medications prior to
the baseline visit
Unwilling to use a barrier method of contraception for the
duration of the study
Intervention
(I)
Type, frequency, dose, duration, prognostic factor Oral spironolactone at an initial dose of 25 or 50 mg/day,
escalating as and if necessary to 100 mg/day after 6–8 weeks
depending on response. Total treatment duration
not\3 months, and preferably 6 months. It is recommended
that concomitant topical therapy is not permitted for any study
versus placebo (comparison one below)
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regarded as ineffective, not recommended [122, 123] or
there is insufficient evidence to support its use [124]. All,
including those that purport to be evidence-based, have
failed to identify the majority of studies that were included
in this systematic review. Although there were five relevant
studies that, to date, have proved unobtainable (two of
which were almost certainly duplicate publications of
included case series), we are confident that all the RCTs
evaluating spironolactone for acne in women have been
retrieved and no clinical trial evidence has been over-
looked. Until such time as higher quality evidence becomes
available, guideline developers will have to continue to
rely on recommendations largely based on expert experi-
ence or reached via consensus of expert panels. While this
review has identified some very-low-quality evidence
which showed that the 200 mg daily dose was statistically
significantly more effective than placebo versus inflamed
lesions, it has also confirmed that this dose is associated
with a significantly greater risk of adverse side effects than
lower doses. Hence, there would appear to be no merit in
using these higher doses for managing acne, except in
exceptional circumstances (e.g. in obese women with
PCOS). Data from the multiple case series suggest that any
future RCT examining lower doses is likely to generate
results that confirm the effectiveness and better safety
profile of doses B100 mg/day.
The findings of this systematic review have several key
implications for future research. First, there is an urgent
need for a well-designed, adequately powered RCT versus
placebo, preferably of monotherapy, so that it is possible to
establish whether spironolactone is effective against
inflamed and non-inflamed lesions without concomitant use
of a topical agent that would inhibit comedogenesis (see
Table 6). Women who are stably maintained on an oral
contraceptive can be considered for inclusion in such a trial
as long as they remain on the oral contraceptive throughout
and have been taking it sufficiently long enough for any
anti-acne effect to be maximalized. If such a study con-
firms the utility of spironolactone, then head-to-head
comparisons versus widely used oral therapies (antibiotics,
Table 6 continued
Element Issues to consider Status of research for this review and recommendations
Comparison
(C)
Type, frequency, dose, duration, prognostic factor In order of priority:
1. Matching placebo
2. An oral antibiotic of known magnitude of effect on acne
3. A combined oral contraceptive with low androgenicity of
known magnitude of effect on acne
Outcome
(O)
Which clinical or patient-related outcomes will the researcher
need to measure, improve, influence, or accomplish? Which
methods of measurement should be used?
1. Change in the number of acne lesions (inflamed and non-
inflamed)
2. Participant-assessed global improvement in acne severity
using a Likert-like scale with photographic anchor at baseline
3. Change in HRQOL assessed using any validated or recognized
quality-of-life instrument or as part of a validated patient-
reported outcome measure
4. Proportion of participants who reported an adverse effect
(putative drug-related adverse event) throughout the study
period; number and type of adverse effects
5. Change in sebum excretion rate on the face using a validated
method
Note clinical outcomes and measures (1–3) may be subject to
change as a result of ongoing work by the Acne Core Outcomes
Research Network
Timelines Time aspects of core elements:
Age of population 18 years and over; premenopausal
Duration of intervention At least 3 months, preferably 6 months




Date of literature search or recommendation November 2016
GRADE Grading of Recommendations Assessment, Development and Evaluation, RCTs randomized controlled trials, IGA Investigator’s Global
Assessment, HRQOL health-related quality of life
a Brown et al. [125]
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COCs, isotretinoin) could follow. The need for, and utility
of, combinations could also be explored. Within these tri-
als, validated outcome measures should be carefully
selected and any dose-related effect on sebum secretion
should be explored early on. Monitoring serum androgens
within such RCTs is unnecessary unless the trial is inten-
ded to identify subgroups of women less/more likely to
benefit based, at least in part, on a combination of hormone
profiles and clinical presentation.
5 Conclusions
This systematic review has revealed a lack of high-quality
evidence on the benefits and potential harms of oral spirono-
lactone for managing acne in women. However, it has shown
that (1) there is low-quality, but statistically highly significant,
evidence that 200 mg/day effectively reduces inflamed lesion
counts; (2) side effects, in particular menstrual irregularities,
are dose-related; and (3) concomitant use of a COC signifi-
cantly reduces the incidence of menstrual disturbances. It has
also confirmed the recommendation of Plovanich et al. [53]
that routine potassium monitoring is largely unnecessary
unless risk factors are present.
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